Low Anticoagulant Heparin (LAH) derivatives

Dilafor is focused on developing innovative pharmaceutical products to address the risks associated with labor, particularly for term pregnant women. Their lead drug candidate, Tafoxiparin, is a proprietary heparan sulfate mimetic that has shown promise in enhancing cervical ripening and facilitating effective labor. Based on extensive research from Karolinska Institutet and Lund University, Tafoxiparin has been demonstrated to significantly improve the cervical ripening rate in clinical studies involving over 650 pregnant women. The results indicate that 59% of women treated with Tafoxiparin experienced spontaneous labor onset or achieved a ripe cervix, suggesting its potential to reduce complications during labor.

The company has successfully completed multiple clinical studies, including a phase IIb trial that confirmed Tafoxiparin's safety and efficacy in term-pregnant women with an unripe cervix. This study revealed that women receiving Tafoxiparin had fewer instrumental deliveries and lower instances of fetal distress compared to those on placebo. Additionally, previous phase I studies have established Tafoxiparin's safety profile and pharmacokinetics, laying the groundwork for further clinical development in obstetric indications. Overall, Dilafor's commitment to research and development aims to provide safer treatment alternatives for labor priming, ultimately contributing to healthier outcomes for mothers and infants.

Sweden

Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications.

Dilafor

Company Details